Successful immune tolerance induction consisting of high-dose factor VIII rich in von Willebrand factor and pulsed intravenous immunoglobulin: A case report

Journal of Medical Case Reports

Volumn 6, Issue , 2012, Pages

  Kubisz, Peter ^a   Plamenova, Ivana ^a   Holly, Pavol ^a   Stasko, Jan ^a  

^a Martinska Fakultna Nemocnica   (Slovakia)

Author keywords

Coagulation factor VIII inhibitor; Hemophilia A; Immune tolerance induction; Intravenous immunoglobulin; Recombinant activated factor VII

Indexed keywords

FANHDI; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; CASE REPORT; CAUCASIAN; CHILD; DRUG MEGADOSE; FOLLOW UP; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; INTRON; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SUBCLAVIAN VEIN; TREATMENT DURATION;

EID: 84867237474     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-6-350     Document Type: Article

References (15)

1. Factor VIII inhibitors: a 50-year perspective. Green D, Haemophilia 2011 17 831 838 10.1111/j.1365-2516.2011.02568.x 21592257
2. Immune tolerance induction for patients with severe hemophilia A: a critical literature review. Franchini M, Lippi G, J Thromb Thrombolys 2011 32 439 447 10.1007/s11239-011-0624-3
3. Immune tolerance induction in haemophilia: evidence and the way forward. DI Michele DM, J Thromb Haemost 2011 9 Suppl. 1 216 225 21781258
4. Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion. Mauz-Korholz C, Korholz D, Gobel U, Thromb Haemost 1997 78 959 9268203 (Pubitemid 27365601)
5. Immune tolerance for the treatment of factor VIII inhibitors-twenty years of the Bonn Protocol. Brackmann HH, Oldenburg J, Schwaab R, Vox Sang 1996 70 30 35 8869466 (Pubitemid 26055992)
6. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Coppola A, Di Minno MN, Santagostino E, Br J Haematol 2010 150 515 528 10.1111/j.1365-2141.2010.08263.x 20573153
7. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. DiMichele D, Haemophilia 2009 15 320 328 10.1111/j.1365-2516.2008.01880.x 18976249
8. Immune tolerance induction (ITI) in haemophilia A with inhibitors: the choice of concentrate affecting success. Kreuz W, Escuriola-Ettingshausen C, Auerswald G, Heidemann P, Kemkes-Matthes B, Schneppenheim R, Haematologica 2001 86 Suppl. 4 16 20 11926766
9. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of patients with severe hemophilia A and high-responding inhibitors. Coppola A, Margaglione M, Santagostino E, Rocino A, Grandone E, Mannucci PM, Di Minno G, for the AICE PROFIT Study Group, J Thromb Haemost 2009 7 1809 1815 10.1111/j.1538-7836.2009.03615.x 19740093
10. Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? Callaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J, Haemophilia 2011 17 483 489 10.1111/j.1365-2516.2010.02429.x 21118335
11. A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Di Minno G, Coppola A, Blood Transfus 2011 9 Suppl. 2 14 s20 21839028
12. Venous access in haemophiliac children: choice and management. Santagostino E, Mancuso ME, Haemophilia 2010 16 Suppl. 1 20 24 20059565
13. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. Benson G, Auerswald G, Elezovi I, Lambert T, Ljung R, Morfini M, Remor E, Salek SZ, Eur J Haematol 2012 88 371 379 10.1111/j.1600-0609.2012.01754.x 22260405
14. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Hay CR, DiMichele DM, Blood 2012 119 1335 1344 10.1182/blood-2011-08-369132 22101900
15. Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin. Stiefel M, Pinkwart C, Haase R, Merkel N, Forsberg D, Mauz-Körholz C, Hämostaseologie 2010 30 Suppl. 1 119 S121 23082321